Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

CareDx Launches Olerup QTYPE® at ASHI  

Posted on: 29 Sep 16

BRISBANE, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced the launch of Olerup QTYPE® at the 42nd Annual Meeting of the American Society of Histocompatability and Immunogenetics (ASHI)  in St. Louis, MO. 

During a lunchtime symposium on the pre-to-post transplant continuum, John Lunz, PhD, from the Gift of Hope Organ and Tissue Donor Network discussed the center’s experience with enhanced resolution in rapid HLA typing of deceased donors. Daniel Brennan, MD from the Washington University at St. Louis spoke about post transplant recipients and immunological guidelines.  Rapid and precise HLA typing is key in transplantation.     

Olerup QTYPE is a robust and easy to use alternative for rapid HLA typing within one hour.  This new test brings several needed features to HLA labs, including speed and precision.  

Olerup QTYPE is currently for use on the Roche LightCycler 480II, a robust and well established RT-PCR instrument.  Validation studies are also underway for the use of Olerup QTYPE on the ABI suite of instruments.    Multiple product demonstrations have been scheduled at several HLA laboratories across the US and Europe.

Olerup QTYPE is the first product to launch following the acquisition of Allenex by CareDx.  “ASHI provides a unique platform for the company to showcase our pre-to-post transplant strategy,” stated Peter Maag, President and CEO of CareDx.  “This new product allows us to build on our expertise and leadership across transplantation.”

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure®, a proprietary next-generation sequencing–based test to detect donor-derived cell-free DNA (dd-cfDNA) after transplantation.

CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing tools used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation.  Olerup QTYPE® offers speed and precision in real time as a rapid HLA typing tool.  XM-ONE® is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit:

Forward Looking Statements
In addition to historical information, this press release contains forward-looking statements with respect to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016 filed by us with the SEC on August 22, 2016, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.


Last updated on: 29/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.